N-(2-chloro-4-diazo-5-methylcyclohexa-2,5-dien-1-ylidene)benzamide;hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-chloro-4-diazo-5-methylcyclohexa-2,5-dien-1-ylidene)benzamide;hydrochloride
• 化学式: C14H11Cl2N3O
• mdl: MFCD00011892
• 分子量: 308.2
• InChiKey: SARKXLKWFKNUMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.02
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Alpha V integrin receptor antagonists
  申请人：——

  公开号：US20010053853A1

  公开（公告）日：2001-12-20

  The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

  本发明涉及新型烷基酸衍生物，其合成以及它们作为αv整合素受体拮抗剂的用途。更具体地说，本发明的化合物是αvβ3和/或αvβ5整合素受体的拮抗剂，可用于抑制骨吸收，治疗和预防骨质疏松症，并抑制血管再狭窄、糖尿病视网膜病变、黄斑变性、血管生成、动脉粥样硬化、炎症性关节炎、癌症和转移性肿瘤生长。
• NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
  申请人：Ryu Jei Man

  公开号：US20110306606A1

  公开（公告）日：2011-12-15

  The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyridine derivative compound of the present invention increases osteoblast activity and effectively inhibits the differentiation of osteoclasts, and thus can be usefully used for the prevention and treatment of osteoporosis.

  本发明涉及一种新型的2,6-取代-3-硝基吡啶衍生物化合物，一种制备该化合物的方法，以及包括该化合物的用于预防和治疗骨质疏松症的药物组合物。本发明的2,6-取代-3-硝基吡啶衍生物化合物增加成骨细胞活性并有效抑制破骨细胞的分化，因此可用于预防和治疗骨质疏松症。
• [EN] NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZAMIDINE, PROCÉDÉ DE PRÉPARATION CORRESPONDANT ET COMPOSITION PHARMACEUTIQUE LES CONTENANT QUI PERMET DE PRÉVENIR OU DE TRAITER L'OSTÉOPOROSE
  申请人：DONG WHA PHARM IND CO LTD

  公开号：WO2009017346A1

  公开（公告）日：2009-02-05

  The present invention relates to novel benzamidine derivatives, a process for the preparation thereof and a pharmaceutical composition for preventing or treating osteoporosis comprising the same. The benzamidine derivatives of the present invention effectively inhibit osteoclast differentiation at an extremely low concentration, and thus can be advantageously used for the prevention and treatment of osteoporosis.

  本发明涉及新型苯甲酰胺衍生物，其制备方法以及包含其的用于预防或治疗骨质疏松症的药物组合物。本发明的苯甲酰胺衍生物在极低浓度下有效抑制成骨细胞的分化，因此可有利地用于预防和治疗骨质疏松症。
• [EN] METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE<br/>[FR] MÉTHODES DE PRÉVENTION OU DE TRAITEMENT DE L'ATHÉROSCLÉROSE AVEC DES INHIBITEURS D'ISOENZYMES SPÉCIFIQUES DE LA NEURAMINIDASE HUMAINE
  申请人：UNIV ALBERTA

  公开号：WO2018213933A1

  公开（公告）日：2018-11-29

  The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.

  本发明提供了一种预防或治疗动脉粥样硬化或其症状的方法，包括向需要的受试者施用神经氨酸酶1（neu1）的特异性抑制剂；神经氨酸酶3（neu3）；或式I的neu1或neu3的双特异性抑制剂；（I）和式I的化合物。
• Alpha v integrin receptor antagonists
  申请人：——

  公开号：US20020049224A1

  公开（公告）日：2002-04-25

  The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. 1

  本发明涉及通过化合物的代谢转化形成的新化合物，包含这种化合物的药物组合物，以及它们作为αvβ3整合素受体拮抗剂的用途。本发明的化合物对于抑制骨吸收、再狭窄、血管生成、糖尿病视网膜病变、黄斑变性、炎症性关节炎、癌症和转移性肿瘤生长具有用途。它们特别适用于抑制骨吸收以及治疗和预防骨质疏松症。

表征谱图